Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
NCT07917182, Not yet recruiting, Chinese University of Hong Kong
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE) | ClinicalTrials.gov |
| NCT number | NCT07917182 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 1,600 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Chinese University of Hong Kong | ClinicalTrials.gov |
| Conditions | Alzheimer s Disease, Mild Cognitive Impairment (MCI) | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Hong Kong Montreal Cognitive Assessment (HK-MoCA) | Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up | The HK-MoCA is a locally validated, brief cognitive screening tool assessing multiple domains including attention, executive function, memory, language, visuospatial ability, and orientation, and is widely used to detect mild cognitive impairment in the Hong Kong Chinese population. The total score is 30. The lower the score, the higher risk of cognitive impairment | ClinicalTrials.gov |
| Primary | Clinical Dementia Rating | Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up | The CDR is a semi-structured interview-based staging instrument that evaluates both cognitive and functional performance across six domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care), yielding a global score that reflects overall severity of cognitive impairment (0 = normal, 0.5 = questionable/very mild, 1 = mild, 2 = moderate, 3 = severe). | ClinicalTrials.gov |
| Primary | Hong Kong List Learning Test | Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up | The HKLLT is a culturally adapted verbal list-learning test modeled after the California Verbal Learning Test, used to assess verbal learning and memory, with Trial 4 (T4, delayed recall) serving as a sensitive index of episodic memory decline. The lower the standard deviation of the Trial 4 recall, the higher the risk of cognitive impairment | ClinicalTrials.gov |
| Primary | Simple Mild Neurocognitive Disorder due to Alzheimer's Disease Risk Test (SMART) | Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up | The SMART is a novel digitalised tool that incorporates both subjective and objective measures of cognitive impairment. it incorporates immediate recall, delayed recall, and verbal fluency tasks. The lower the z-score, the higher the risk of cognitive impairment | ClinicalTrials.gov |
| Secondary | The pathological findings and changes in SUVR on PET imaging | baseline and 3 year follow up | An amyloid PET (Positron Emission Tomography) scan measures beta-amyloid plaques in the brain which lead to Alzheimer's disease (AD) pathogenesis. One of the key quantitative measurements is Standarized uptake value ratio (SUVR) . The higher the value of SUVR reflect greater amyloid accumulation in the brain. | ClinicalTrials.gov |
| Secondary | The pathological findings and changes on MRI | baseline and 3 year follow up | A MRI brain scan mainly investigate and measure the structure of the brain. Volume of specific brain regions (such as the hippocampus, ventricles, or total gray/white matter) in cubic centimeters (cm³) | ClinicalTrials.gov |
| Secondary | The pathological findings and changes in Centiloid Scale on PET imaging | baseline and 3 year follow up | An amyloid PET (Positron Emission Tomography) scan measures beta-amyloid plaques in the brain which lead to Alzheimer's disease (AD) pathogenesis. Another key quantitative measurement is Centiloid Scale (CL) . The higher the value of CL reflect greater amyloid accumulation in the brain. | ClinicalTrials.gov |
| Other | Blood biomarkers | Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up | Biomarkers will include molecular and cellular assays, genomic, epigenomic, and other multi-omic assays for both cellular and acellular fractions. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 39
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 8232972 | BACKGROUND | PubMed |
| 16466588 | BACKGROUND | PubMed |
| 17466414 | BACKGROUND | PubMed |
| 23097740 | BACKGROUND | PubMed |
| 23737408 | BACKGROUND | PubMed |
| 23842566 | BACKGROUND | PubMed |
| 25125421 | BACKGROUND | PubMed |
| 25348064 | BACKGROUND | PubMed |
| 25385447 | BACKGROUND | PubMed |
| 28488154 | BACKGROUND | PubMed |
| 29653606 | BACKGROUND | PubMed |
| 29878075 | BACKGROUND | PubMed |
| 30114417 | BACKGROUND | PubMed |
| 31039256 | BACKGROUND | PubMed |
| 31467257 | BACKGROUND | PubMed |
| 34838239 | BACKGROUND | PubMed |
| 35908251 | BACKGROUND | PubMed |
| 36043139 | BACKGROUND | PubMed |
| 36192349 | BACKGROUND | PubMed |
| 36279115 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Verbal Fluency | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)